Global High Resolution Melting Research Report 2023: Market to Reach $385.6 Billion by 2030 - Clinical Diagnostics be the Fastest-growing Segment - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "High Resolution Melting Analysis Market Size, Share & Trends Analysis Report By Product (Instruments, Reagents, Software), By Application (Mutation Scanning, Zygosity Testing), By End-use, By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.

The global high resolution melting analysis market size is expected to reach USD 385.6 billion by 2030, growing at a CAGR of 3.32% from 2023 to 2030

Increasing incidences of cancer, sickle cell anemia, HIV and other STDs are expected to positively reinforce demand for smart and simple molecular diagnostics.

Based on analyzing the disease trends and relatively lower treatment rates suggests that the demand for gene mutation and other genomic tests are expected to increase significantly over the next few years. Recent developments in the field of QPCR, next generation sequencing, genomics and big data analytics have been instrumental in strengthening the precision medicine approach. The U.S. FDA has already approved some of the treatments which are designed to meet the requirements of a specific genetic makeup or the genomic profile of the patient's tumor.

For instance, the U.S FDA has approved a new treatment for cystic fibrosis (CF) in January, 2012. The drug kalydeco was approved for patients reported to have a specific genetic mutation known as "G551D mutation. The number of mutations which can lead to CF is in hundreds, and the G551D mutation is responsible for nearly 4% of the cases in the U.S.

Furthermore, in 2015, the Obama administration has announced the Precision Medicine Initiative with an investment of USD 216 million in the 2016 president's budget. This initiative is expected to positively reinforce the HRM analysis market over the forecast period.

High Resolution Melting Analysis Market Report Highlights

• Clinical diagnostics is anticipated to be the fastest-growing segment, with a CAGR of 4.6% through 2030
• The detection of acquired mutations/mutation scanning/SNP typing segment held a significant revenue share in 2022 and the segment is also expected to advance at a significant CAGR over the forecast period.
• In 2022, North America dominated the overall HRM analysis market with a share of nearly 45%. Key factors attributed are high disease prevalence rates, presence of large number of academic universities; strong pharmaceutical and biotech industry, presence of large number genetic testing centers, and rapid adoption of novel technologies for improving the healthcare outcomes.
• Asia pacific is identified as the fastest growing region over the forecast period. Key reasons attributed are increasing public and private expenditure on molecular diagnostics and genetic testing, increasing prevalence of genetic disorders, and increasing burden of chronic diseases such as cancer, COPD, HIV and others.

Competitive Landscape

• Thermo Fisher Scientific Inc.
• Bio-Rad Laboratories, Inc.
• F. Hoffman-La Roche Ltd.
• Bio Farma
• QIAGEN
• Illumina, Inc.
• Agilent Technologies, Inc.
• BIOMERIEUX
• Meridian Bioscience, Inc.
• Novacyt
• PREMIER Biosoft
• Azura Genomics Inc.
• CANON MEDICAL SYSTEMS CORPORATION

For more information about this report visit https://www.researchandmarkets.com/r/yoe5d4

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900